Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Guggenheim in a note issued to investors on Tuesday,Benzinga reports. Weiss Ratings cut Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Chardan Capital reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. Get Stoke Therapeutics alerts:Get Our Latest Stock Analysis on Stoke TherapeuticsStoke Therapeutics Price PerformanceShares of Stoke Therapeutics stock traded up $0.53 on Tuesday, hitting $30.09. Further ReadingReceive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.